129 related articles for article (PubMed ID: 38070598)
1. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
[TBL] [Abstract][Full Text] [Related]
2. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
3. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract][Full Text] [Related]
4. Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
Huang Z; Zhang Y; Xu Q; Song L; Li Y; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zeng L; Zhang Y
Lung Cancer; 2024 Jun; 192():107827. PubMed ID: 38795459
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.
Zeng L; Li Y; Xiao L; Xiong Y; Liu L; Jiang W; Heng J; Qu J; Yang N; Zhang Y
Onco Targets Ther; 2018; 11():6937-6945. PubMed ID: 30410351
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.
Nadal E; Rifi N; Kane S; Mbacke S; Starkman L; Suero B; Le H; Samjoo IA
Lung Cancer; 2024 Jun; 192():107816. PubMed ID: 38749072
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
10. Detection of
Li N; Chen Z; Huang M; Zhang D; Hu M; Jiao F; Quan M
Front Cell Dev Biol; 2022; 10():1035033. PubMed ID: 36589752
[No Abstract] [Full Text] [Related]
11. Different Types of
He Y; Sheng W; Hu W; Lin J; Liu J; Yu B; Mao X; Zhang L; Huang J; Wang G
Oncol Res; 2019 Aug; 27(8):901-910. PubMed ID: 30940295
[No Abstract] [Full Text] [Related]
12. A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma.
Lan S; Li H; Liu Y; Xu J; Huang Z; Yan S; Zhang Q; Cheng Y
Onco Targets Ther; 2020; 13():11499-11504. PubMed ID: 33204104
[TBL] [Abstract][Full Text] [Related]
13. Serial Cell-Free DNA Sequencing in
Choudhury NJ; Jun Woo H; Chen M; Shah R; Donoghue M; Berger M; Drilon A
JCO Precis Oncol; 2024 Jun; 8():e2300721. PubMed ID: 38848521
[TBL] [Abstract][Full Text] [Related]
14. Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment.
Zhang X; Wang B; Wang C; Liao C; Wang S; Cao R; Ma T; Wang K
Front Oncol; 2022; 12():1021342. PubMed ID: 36387218
[TBL] [Abstract][Full Text] [Related]
15. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC
Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003
[TBL] [Abstract][Full Text] [Related]
16. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer.
Li W; Wan R; Guo L; Chang G; Jiang D; Meng L; Ying J
BMC Med; 2022 May; 20(1):160. PubMed ID: 35534835
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
18. Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study.
Zhou S; Zhang F; Xu M; Zhang L; Liu Z; Yang Q; Wang C; Wang B; Ma T; Feng J
Mol Oncol; 2023 Oct; 17(10):2200-2212. PubMed ID: 37584407
[TBL] [Abstract][Full Text] [Related]
19. Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC.
Li W; Liu Y; Li W; Chen L; Ying J
J Thorac Oncol; 2020 Jul; 15(7):1223-1231. PubMed ID: 32151779
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.
Shu Y; Li H; Shang H; Chen J; Su X; Le W; Lei Y; Tao L; Zou C; Wu W
Onco Targets Ther; 2020; 13():10387-10391. PubMed ID: 33116618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
